Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16388417 | 0.92 | TSHR (0.55) | CA1CA2SLC1A1TSHRCA12 | |
| SCHEMBL9508659 | 0.89 | CA2 (0.67) | CA1CA2SLC1A1TSHRTDP1 | |
| SCHEMBL9506213 | 0.89 | CA1 (0.56) | CA1CA2SLC1A1TSHRHDAC7 | |
| SCHEMBL3918683 | 0.87 | CA1 (0.61) | CA1CA2SLC1A1TSHRHDAC7 | |
| SCHEMBL28042796 | 0.87 | CA1 (0.55) | CA1CA2TSHRTDP1CYP3A4 | |
| SCHEMBL9509840 | 0.86 | CA1 (0.62) | CA1CA2SLC1A1TSHRZDHHC7 | |
| SCHEMBL11069370 | 0.84 | SLC1A1 (0.47) | CA1CA2SLC1A1TSHRHDAC7 | |
| SCHEMBL18264427 | 0.84 | CA1 (0.50) | CA1CA2TSHRHDAC7HDAC8 | |
| SCHEMBL8107918 | 0.84 | TSHR (0.54) | CA1CA2SLC1A1TSHRZDHHC7 | |
| SCHEMBL18264428 | 0.84 | TSHR (0.52) | CA1CA2SLC1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418030-B1 | CURING AGENT COMPOSITION | KAO CORP (JP) | 2019-09-25 | — | — | EP | claimed |
| CN-102387877-A | Curing agent composition | KAO CORP | 2012-03-21 | — | — | CN | claimed |
| US-20120043694-A1 | CURING AGENT COMPOSITION | KAO CORPORATION (JP) | 2012-02-23 | — | — | US | claimed |
| EP-2418030-A1 | CURING AGENT COMPOSITION | Kao Corporation (JP) | 2012-02-15 | — | — | EP | claimed |
| EP-2418030-B1 | CURING AGENT COMPOSITION | KAO CORP (JP) | 2019-09-25 | — | — | EP | disclosed |
| EP-2581148-B1 | PROCESS FOR PRODUCTION OF MOLDS | KAO CORP (JP) | 2018-10-24 | — | — | EP | disclosed |
| US-9976165-B2 | Methods for increasing molecular diversity of polyketides and non-ribosomal proteins | ISOMERASE THERAPEUTICS, LTD. (GB) | 2018-05-22 | — | — | US | disclosed |
| CN-105348185-B | Bicyclic [3.2.1] octyl group amide derivatives and application thereof | H.隆德贝克有限公司 | 2018-02-16 | — | — | CN | disclosed |
| CN-107531693-A | Novel 5 or 8-substituted imidazo [1, 5-a ] pyridines as inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 百济神州有限公司 | 2018-01-02 | — | — | CN | disclosed |
| US-20170101659-A1 | METHODS FOR INCREASING MOLECULAR DIVERSITY OF POLYKETIDES AND NON-RIBOSOMAL PROTEINS | Isomerase Therapeutics Ltd. (GB) | 2017-04-13 | — | — | US | disclosed |
| US-9505773-B2 | Rapamycin analogues and their pharmaceutical use | Isomerase Therapeutics Ltd. (GB) | 2016-11-29 | — | — | US | disclosed |
| US-20160176893-A1 | RAPAMYCIN ANALOGUES AND THEIR PHARMACEUTICAL USE | ISOMERASE THERAPEUTICS, LTD. (GB) | 2016-06-23 | — | — | US | disclosed |
| EP-2581148-A1 | PROCESS FOR PRODUCTION OF MOLDS | Kao Corporation (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-20120261087-A1 | PROCESS FOR PRODUCING A MOLD | KAO CORPORTATION (JP) | 2012-10-18 | — | — | US | disclosed |
| CN-102665961-A | Process for production of molds | KAO CORP | 2012-09-12 | — | — | CN | disclosed |
| CN-102387877-A | Curing agent composition | KAO CORP | 2012-03-21 | — | — | CN | disclosed |
| US-20120043694-A1 | CURING AGENT COMPOSITION | KAO CORPORATION (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-2418030-A1 | CURING AGENT COMPOSITION | Kao Corporation (JP) | 2012-02-15 | — | — | EP | disclosed |
| EP-0338427-B1 | PROCESS FOR THE PREPARATION OF ESTERS OLEFINIC UNSATURATED CARBOXYLIC ACIDS WITH A TERMINAL ESTER GROUP | BASF Aktiengesellschaft (DE) | 1993-08-18 | — | — | EP | disclosed |
| EP-0338427-A2 | Process for the preparation of esters olefinic unsaturated carboxylic acids with a terminal ester group | BASF Aktiengesellschaft (DE) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176893-A1 | RAPAMYCIN ANALOGUES AND THEIR PHARMACEUTICAL USE | FKBP1A, FKBP1B, FKBP2 | CA1 4726/4885CA2 3673/4885SLC1A1 4564/4885 |
| US-20120043694-A1 | CURING AGENT COMPOSITION | ERG28, SMARCA5, MYB | CA1 2337/4885CA2 3521/4885SLC1A1 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.